May 2023 DHC Newsletter
FEATURE:?Social Determinants of Health and the Role of Digital in Optimizing Patient Outcomes and Care
Non-clinical barriers represent an opportunity to increase drug treatment rates by ~10% and branded treatment rates by ~5%.???This latest patient data from ZS Associates succinctly demonstrates why the May DHC Virtual Summit focused on Social Determinants of Health.?Members of the DHC Expert Network have told us recently that understanding and addressing SDOH is rapidly rising as a top priority for those in commercial roles. With table stakes such as the possibility of increasing the number of patients on therapy by 50+%, it’s become mission critical on an organizational level for pharmaceutical companies to take an active role in solving for these gaps.
Of course, there’s a virtually universal agreement around the responsibility to do our part as an industry.?Those of us who have worked in pharma for any length of time can tell you that it’s the personal commitment to improving patient health outcomes that keeps us in the job. The desire to do “good” and make a difference in the lives of individuals who are facing non-clinical/non-biological barriers to treatment is the shared thread for marketers who have long-kept SDOH on the agenda.
On May 24, DHCG Executive Director, Christine Franklin, was joined by Merck’s Heath Morlok as session co-moderator. Those who attended live were able to ask questions, interact with speakers, and hear moderator analysis and key-takeaways, with a focus on oncology patients.?A summary and presentation videos from the sessions are available now. We encourage you to go back and watch them if you missed the live sessions, or want to be inspired once again.
Additional Oncology Trends Features
Oncology is Increasingly Competitive – Here’s How to Stand Out - Ervasana Intouch
It’s an exciting era in oncology: many new drugs with increasing benefits and more tolerable profiles are being developed and released, and that means that nearly all tumor type spaces are becoming more competitive. In the fast-changing therapeutic landscape of oncology, there are three things smart marketers do to successfully communicate their value.
A Sign of Something Larger: The FDA’s Recent Draft Guidance for Oncology Medicines - Syneos Health
The Food and Drug Administration (FDA) recently issued draft guidance for the life sciences industry on clinical trial considerations to support accelerated approval of oncology drugs. But what is the real driving force for this close examination of clinical trial design? Understanding this broader context can help manufacturers best position themselves in the evolving world of FDA regulatory requirements and access & payment models (such as the CMS Innovation Center’s recently announced three test models).?
Physician Perspective: Social Determinants of Health and the Enhancing Oncology Model - PatientPoint?
Dr. Kashyap Patel, CEO, Carolina Blood and Cancer Care Associates, discusses how oncology practices are leveraging digital tools to screen for SDOH to meet quality care goals under the new Enhancing Oncology Model.?
Closing the knowledge gap for cancer patients: 3 ways - Phreesia
Many cancer patients are unaware of important aspects of their condition and treatment options, according to results from 825 patients diagnosed or treated for cancer who were surveyed on our PatientInsights platform in 2022 while checking in for their doctors’ appointments. How can the industry address this knowledge gap? We uncovered cancer patients’ perceptions about their treatment journeys, as well as optimal ways to improve understanding of their disease and available support resources.?
Every Message, Everywhere, All at Once: Oncologist Brand Engagement Preferences - OptimizeRx
OptimizeRx recently surveyed 120+ physicians across six specialty areas, including oncology, and found they are everywhere, all at once, looking for information from life science brands. We asked a wide range of highly specific questions related to where and when they are engaging with life science brands, their preferred channels, the knowledge gaps they are trying to fill, and when specific information is most valuable. Download our oncology data snapshot, or one of our other specialty area snapshots, and discover the information specialists in your therapeutic area are seeking, and what channels they rely on – and trust.
Webinar: HCP Sentiment Series Part 12: Social Media Impact, Medical Congresses & The Patient Dynamic Among Oncologists - Sermo
Don’t miss Sermo’s upcoming HCP Sentiment webinar – this time, all things Oncology. Join us for a 30-minute walkthrough of insights from our global oncology community to help inform your outreach and engagement strategy.
Upcoming Webinar
Click on image to register
Additional SDOH Insights
领英推荐
Rx Cost Series: Improving Adherence Through Inclusivity - Healthline Media
The latest blog in our Rx Cost Series examines how pharma marketers can improve adherence through diversity and inclusivity. Explore how different demographics face challenges in their health journeys and learn about the impact of education on behavior. Plus, find out how Healthline Media is partnering with pharma brands to tackle affordability barriers for all.
Women's Health is Health: How Brands Can Equitably Deliver on What Women Need - CMI Media Group
CMI Media Group has released new insights on women’s health and disparities in treatment, access, and education. When asked about the messages women most often seek from healthcare companies, 54% of women diagnosed with cancer responded they want more information related to their oncology journey (in comparison to 41% of men). Our industry has a responsibility to deliver information in a tailored-to-women format. (Source: Media Vitals? 2023.)
Life Sciences Brands The business imperative for health equity in life sciences: Repairing the patient journey - ZS
ZS's Research Center conducted a study focused on identifying the health inequities and drivers of those inequities along the patient journey within and across various diseases. Life sciences companies can leverage the insights uncovered in our study to prioritize areas of focus, design better customer engagement programs and make a tangible impact on patient outcomes.
Additional Industry Content
How HCP Engagement is Evolving - imre Health via PM360online
imre Health’s Vice President of Digital Experience, Alex Sophocles, among other industry experts, provides his perspective on the best model for engaging with HCPs now given changes in recent years. Check out Alex’s thoughts on the dawn of medium agnostic marketing from PM360online.
Arm Your Field Teams for Success: Optimize Your Medical Device Sales Process - Underscore Marketing
When done right, media can be one of your field team's greatest assets. But there is far more to it than click-through-rates and impressions. Read this keynote presentation prepared by Underscore EVP, Chris Tuleya, and understand how data can be used as a potent tool for field teams to have more informed discussions that help boost the medical device sales process.
Evolving People Management to Match Pharma’s Pace of Change - North Highland
Despite major, rapid changes across the industry, Life Sciences’ workforce management strategies remain largely unchanged. But Life Sciences organizations can become employers of choice for a new wave of talent that values purpose over profits and personal development over corporate growth. Digital accelerators and people-centered adoption efforts can cultivate a workforce that is resilient, adaptable, and driven by data, enabling faster breakthroughs and better positioning the current workforce to re- and up-skill for future needs.
Synchronizing Sales and Marketing: Boost Campaign Effectiveness by 23%?- Veeva Systems
Today, over 70% of HCPs engaged by field teams are not being promptly reached by digital advertising. Insights from Veeva Crossix and Veeva CRM data show why brands that synchronize sales and marketing activities are experiencing an increase in marketing effectiveness.?
Short Take